Advances in molecular genetics have revealed that approximately 30% of cases with steroid-resistant nephrotic syndrome (SRNS) are caused by single-gene mutations. More than 50 genes are responsible for SRNS. One such gene is the nucleoporin, 93-KD (NUP93). Thus far, few studies have reported mutations of NUP93 in SRNS. Here, we describe an NUP93 biallelic mutation in a 9-year-old boy with focal segmental glomerular sclerosis (FSGS). Notably, one mutation comprised an intronic variant; we conducted in vivo and in vitro analysis to characterize this variant. We found two heterozygous mutations in NUP93: c.2137-18G>A in intron 19 and a novel nonsense mutation c.727A>T (p.Lys243*) in exon 8. We conducted RNA sequencing and in vitro splicing assays by using minigene construction, combined with protein expression analysis to determine the pathogenicity of the intronic variant. Both RNA sequencing and in vitro splicing assay showed exon 20-skipping by the intronic variant. In protein expression analysis, aberrant subcellular localization with small punctate vesicles in the cytoplasm was observed for the intronic variant. Taken together, we concluded that c.2137-18G>A was linked to pathogenicity due to aberrant splicing. NUP93 variants are quite rare; however, we have shown that even intronic variants in NUP93 can cause SRNS. This study provides a fundamental approach to validate the intronic variant, as well as new insights regarding the clinical spectrum of SRNS caused by rare gene variants.
Introduction
The most common form of nephrotic syndrome in childhood is idiopathic nephrotic syndrome (INS) [1] , which is characterized by massive proteinuria, hypoalbuminemia, edema, and hyperlipidemia [2] . Most children with INS are steroid-responsive and experience favorable outcomes. Approximately 10-20% of children with INS do not respond to steroid therapy; this disease presentation is known as steroid-resistant nephrotic syndrome (SRNS), and is frequently accompanied by focal segmental glomerulosclerosis (FSGS). Notably, 20-40% of patients with SRNS progress to end-stage renal disease (ESRD) [3, 4] .
Advances in molecular genetics have revealed that approximately 30% of SRNS cases are caused by singlegene mutations, highly expressed in podocytes [5] . More than 50 genes are responsible for SRNS [6] . One such gene is the nucleoporin, 93-KD (NUP93).
The NUP93 protein is a critical component of large molecule assemblies (approximately 125 MDa), so-called nuclear pore complexes (NPCs) embedded in the nuclear envelope [7] . NPCs are large channels that cross the nuclear envelope, which mediate nucleocytoplasmic transport. They consist of multiple copies of nucleoporin (NUP) proteins [8] . Most NUPs are symmetrically distributed in NPCs, building a symmetric core that is decorated with asymmetric nucleoporins on the nuclear and cytoplasmic ends [9] . There are two major scaffolding modules in NUPs that compose a symmetric structure, which span the inner and outer nuclear membranes to form a central channel [10] . Those scaffolding modules orchestrate the NUP93 complex by directly or indirectly interacting with other NUPs (NUP53, NUP155, NUP188, and NUP205) at the C-terminal alpha-helical domain of NUP93 [11] [12] [13] . It has been reported that the coiled-coil domain of NUP93 at the N-terminus is essential for recruiting the NUP62 complex, which comprises FGNUPs rich in FG (Phe and Gly residues)-repeats; this complex modulates the permeability barrier of the pore [11] . Therefore, NUP93 has a pivotal role in the NPC to organize nuclear pore architecture, the disruption of which induces aberrant NPC assembly and subsequent dysfunction of nucleocytoplasmic transport.
Thus far, only two studies have reported mutations of NUP93 in SRNS [14, 15] . Herein, we describe a NUP93 biallelic mutation in a 9-year-old boy with FSGS: one mutation was a novel heterozygous truncating variant, whereas the other was a heterozygous intronic variant, the pathogenicity of which was unknown. To confirm the pathogenicity of the intronic variant, we conducted in vivo and in vitro mRNA analysis, as well as in vitro protein expression analysis.
Methods

Patient
The patient was a 9-year-old Russian boy. He exhibited proteinuria at 2 years old, and was diagnosed with SRNS. Histological findings showed FSGS. At the onset, hypoalbuminemia (2.6 g/dL), high serum creatinine (0.88 g/dL) with decreased renal function (estimated glomerular filtration rate: 53.6 L/min/m 2 BSA), proteinuria (urine protein creatinine ratio: 2.37), and hematuria were found. The patient exhibited optic nerve atrophy as an extrarenal symptom. There was no family history of kidney diseases ( Supplementary Fig. 1 ).
Genomic DNA analysis
DNA was isolated from a peripheral blood sample by using a QuickGene DNA whole blood kit (Kurabo, Kurashiki, Japan). Next-generation sequencing samples were prepared by using a HaloPlex target enrichment system kit (Agilent Technologies, Santa Clara, CA, USA), in accordance with the manufacturer's instructions. NUP93 and other podocyte-related gene sequences were determined by targeted sequencing with a next generation sequencer (MiSeq; Illumina, San Diego, CA, USA); variant calling was performed by using a SureCall 4.0 software (Agilent Technologies). Primer pairs were constructed to amplify exons 8 and 20, as well as flanking introns including the variant sequence, which were identified by next generation sequencing. PCR and the direct sequencing method were used to confirm the DNA sequence by using an automated DNA sequencer (3130 Genetic Analyzer; Thermo Fisher Scientific, Waltham, MA, USA).
RNA sequence
Total RNA was extracted from peripheral blood leukocytes by using the RiboPure™ Kit (Thermo Fisher Scientific), followed by reverse transcription using RNA to cDNA EcoDry Premix (Double Primed) (Takara Bio, Shiga, Japan). cDNA was amplified with 40 reaction cycles by using a forward primer at exon 15 (5′-GGAGAAAA CATGTTTCTGCGCT-3′) and a reverse primer at exon 22 (5′-CAGCAAAGGTAATCAGAGTGCG-3′); agarose gel analysis was then performed. Purified PCR products were subcloned into the pT7Blue T vector (Novagen, Darmstadt, Germany) and subjected to direct sequencing.
To confirm the compound heterozygosity, cDNA was amplified with 40 reaction cycles by using a forward primer at exon 5 (5′-CAGCGAATTCTGCACACAC-3′) and a reverse primer at exon 21 (5′-GATGGACTTGTCCCCTT GAG-3′); agarose gel analysis was then performed. Purified PCR products were subjected to subcloning.
In vitro splicing assay
A hybrid minigene was constructed by using the H492 vector, based on the pcDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA, USA), to mimic in vivo splicing [16, 17] . The vector was linearized by inverse PCR with the YH303 forward primer (5′-GGTACCAC AGCTGGATTACTCGCT-3′) and the YH304 reverse primer (5′-GTGAGAGACTTAACTGGCTGC-3′). We amplified genomic DNA from both patient and wild-type peripheral leukocytes to create hybrid minigene by using primers for NUP93 intron 18 to intron 21, which were designed complementary to the ends of the linearized vector by the primer design tool for In-fusion (HD Cloning Kit, Takara Bio). This enabled cloning of the PCR products into the multiple cloning site of the vector, located within an intron between exons A and B. Linearized vector and amplified genomic DNA from both patient and wild-type leukocytes then underwent purification. We designed the in-fusion cloning reaction, then transformed competent Escherichia coli HST08 premium competent cells (Takara Bio).
Hybrid minigenes were checked by sequencing, then transfected into HEK293T and HeLa cells by using Lipofectamine ® 2000 (Thermo Fisher Scientific). Twenty-four hours later, total RNA was extracted from cells by using the RNeasy ® Plus Mini Kit (QIAGEN, GmbH, Hilden, Germany). One microgram of total RNA was subjected to reverse transcription by using the RNA to cDNA EcoDry Premix (Double Primed) (Takara Bio), and PCR was performed with a forward primer corresponding to a segment upstream of exon A (YH307: 5′-ATTACTCGCTCA GAAGCTGTGTTGC-3′) and a reverse primer complementary to a segment downstream of exon B (Y308: 5′-CTGCCAGTTGCTAAGTGAGAGACTT). PCR products were analyzed by electrophoresis on a 1.5% agarose gel, followed by Sanger sequencing.
In vitro protein expression analysis
Protein expression analysis NUP93 cDNAs (NM_001242795.1, isoform 2) from patient and wild-type leukocytes were subcloned into the pcDNA3.1 TOPO vector (Thermo Fisher Scientific). NUP93 isoform 2 (NM_001242795.1; 696aa, a shorter Nterminus) has an in-frame start codon at exon 5 of NUP93 isoform 1 (NM_014669.4; 819aa); both isoforms contain the necessary and sufficient C-terminal domain to form NPCs [11] . N-terminally V5-tagged NUP93 isoform 2 was obtained through PCR amplification by using the following primers (forward with V5-tag (underlined sequence): 5′-GC CATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTC TCGATTCTACGTCTAGAGCTGAGGAGTACCATCGG GAGTCAA-3′, reverse: 5′-GCACTTAATTCATGAG-GACCTCCA-3′). Consequently, we obtained three types of plasmids in the pcDNA3.1 TOPO vector: wild-type and variants of truncating (c.727A>T) and exon 20-skipping (c.2137_2220del). In addition, because only full-length cDNA of isoform 2 (but not of isoform 1) could be cloned from affected individual leukocytes, full-length NUP93 cDNA (NM_014669.4) from human kidney cDNA (Clontech Laboratories, Mountain View, CA, USA) was cloned into the pAcGFP-1-C1 vector (Clontech Laboratories). We obtained three types of plasmids: wild-type and mutagenesis variants of truncating (c.727A>T) and exon 20-skipping (c.2137_2220del). All plasmids were transfected into HeLa cells and mouse podocytes [18] (immortalized mouse podocytes from Katsuhiko Asanuma, Chiba University, Chiba, Japan) with Lipofectamine ® 3000. Cells were fixed with 4% paraformaldehyde in PBS and permeabilized with 0.1% Triton X-100 in PBS, followed by blocking with 5% BSA in PBS. The cells were incubated with primary antibodies [14] (rabbit anti-V5 For western blotting, Mini-PROTEAN TGX Precast Gels (Bio-Rad, Hercules, CA, USA) were run under standard conditions, with 40 µg loaded in each lane. The gel was placed in transfer buffer and transferred to a polyvinylidene fluoride membrane at 200 mA for 30 min. The membrane was rinsed in Tris-buffered saline, followed by rinsing in blocking buffer (block ACE, Bio-Rad) overnight. After rinsing with wash buffer, the membrane was incubated with horseradish peroxidase-conjugated anti-rabbit antibody (Cell Signaling Technology, Danvers, MA, USA) for 90 min at 1:50,000. After final washing, the membrane was developed using ECL chemiluminescence reagent (Amersham Biotech, Amersham, UK).
In silico splicing assay
We predicted splicing domain strength in the intron 19 variant by using the Human Splicing Finder (HSF) (http://www.umd. be/HSF3/HSF.shtml) and SVM-BP Finder (http://regula torygenomics.upf.edu/Software/SVM_BP/).
Results
Genomic DNA and mRNA analysis
Next generation sequencing analysis of the patient revealed two heterozygous mutations on NUP93 (NM_014669.4;16q13): in exon 8, c.727A>T, p.Lys243*, and in intron 19, c.2137-18G>A. The same results were obtained from Sanger sequencing analysis (Fig. 1) . The variant in intron 19 has been reported as rs376379631, with allele frequencies of 0.0001391 (13/9348) in Jewish individuals and 0.0003688 (46/124718) in non-Finnish European individuals (gnomAD). To confirm splicing abnormality in the intron 19 variant, we conducted transcript analysis and detected exon 20-skipping between NUP93 exon 19 and exon 21 (Fig. 2) . This in vivo finding suggested pathogenicity of the intron 19 variant. A segregation study could not be performed because the patient's father's DNA sample was not obtained; however, it was confirmed that the intronic variant (c.2137-18G>A), but not the nonsense variant (c.727A>C), was present in the patient's mother (Supplementary Fig. 1 ). In addition, compound heterozygosity was revealed by subcloning of two types of transcripts in the patient's cDNA, which consisted of either nonsense mutation or exon-20-skipping bands (Supplementary Fig. 2 ).
In vitro splicing assay
For further in vitro investigation of c.2137-18G>A, hybrid minigenes were constructed by inserting the genomic DNA sequence from exon 19 to 21, with the up-and down-stream flanking introns of the NUP93 gene, into the dedicated exon-trapping vector. The mature mRNA obtained from in vitro splicing in HEK293T or HeLa cells was reversetranscribed into cDNA and amplified with specific primers. PCR products were analyzed in an agarose gel, indicating only one band in the control in both HEK293T and HeLa cells; the size of this band was equivalent to the cDNA sequence yielded from putative in vitro splicing. Sequencing analysis of the single band proved that the predicted exons exclusively proceeded to form mature mRNA by splicing of all introns. In comparison, one additional shorter band was detected in the patient in both cell lines; subsequent sequencing analysis demonstrated that in-frame exon 20-skipping was present in the shorter cDNA (Fig. 3) . Note that much higher content of exon 20-skipping cDNA was observed in HEK293T cells, compared with HeLa cells; this may be because regulatory factors related to splicing differ between tissues or cell types. These results were concordant with the analysis of mRNA extracted from peripheral blood leukocytes, indicating that c.2137-18G>A was the causative variant for exon-20-skipping in NUP93 mRNA.
In vitro protein expression analysis
To address the subcellular localization of NUP93 variants, wild-type and two variants of p.Lys243* and p.Ile713_I-le740del (exon 20-deletion) were overexpressed in HeLa cells (Fig. 4 for isoform 2, Supplementary Fig. 3 for isoform 1) and mouse podocytes ( Supplementary Fig. 4 for isoform 1). As expected, expression of truncating variant pLys243* was scarcely observed, proving obvious pathogenicity. Subcellular localization of the exon 20-deleted variant was observed in a punctate pattern, represented as small vesicles scattered throughout the cytoplasm, whereas the wild-type protein was primarily restricted to the nuclear membrane. These results suggested that the aberrant expression and subcellular localization of NUP93 were induced by the loss of exon 20, despite its small size with respect to the inframe deletion. Western blotting revealed that mutant cDNAs of NUP93 showed reduced expression of NUP93 protein level in HeLa cells ( Supplementary Fig. 5 ). These data implied that the compound heterozygous mutation of c.727A>T (p.Lys243*) and c.2137-18G>A in the NUP93 gene could be involved in the onset of SRNS in the affected individual.
In silico analysis of intron 19 variant
To predict the influence of the intronic variant (c.2137-18G>A) on consensus splice sites and enhancer elements, we conducted in silico analysis. The Human Splicing Finder showed that c.2137-18G>A led to no significant alterations on the consensus 5′ and 3′ splice sites (reference score: 7.92; mutation score: 7.18; variation: −9.34%, Supplementary Fig. 6 ). With regard to the potential branch point algorithm, no branch point motif was found in intron 19. The intronic enhancer motifs extracted by ESE finder matrices and predicted ESE octamers demonstrated that the intronic splicing enhancer [12] motif in intron 19 was predicted to be broken (variation −100%) ( Supplementary  Fig. 7 ). The SVM-BP Finder showed no difference in polypyrimidine tract length and score between affected individual and control ( Supplementary Fig. 8 ). These analyses indicated that the splicing alteration might occur as a result of ISE aberration, but not aberrations of splice sites, branch points, or the polypyrimidine site, which highlights the need to clarify the pathogenicity of the variant by further biological investigation (Supplementary Fig. 9 ).
Discussion
In this study, we found two heterozygous mutations on NUP93 in a patient with SRNS. One mutation was a nonsense variant, and its pathogenicity was obvious. To verify the pathogenicity of the intronic variant (c.2137-18G>A), it was necessary to define the aberrant splicing by using mRNA from the patient's sample. This analysis revealed that the intronic variant caused exon skipping. The intronic variant was not localized on an apparent splice site, such as a splicing consensus site or branch point. Moreover, it did not change polypyrimidine tract sequences. Therefore, we conducted an in vitro splicing assay to confirm aberrant splicing by the intronic variant. As was expected, the result showed exon 20-skipping that was identical to the RNA sequencing result obtained with the patient's sample. The reverse transcript product obtained from mature mRNA in HeLa cells by minigene assay revealed a lower amount of the exon-20-skipping band than that in HEK293T cells; this might have been because of differences in splicing regulatory factors between the cell lines. This is a notable limitation of the in vitro splicing assay in our study. To form mRNA, introns must be removed by splicing; then, exons must be ligated together by the molecular "tailor" of the cell, the spliceosome [1] . During splicing, the spliceosome must manage a number of challenges, including matching of correct conserved sequence elements of the pre-mRNA. The consensus sequences are the 5′ splice site (n/GUAUGU), branch point sequence, polypyrimidine tract, and 3′ splice site (YAG/n) [19] . Mutations involving variant GT and AG nucleotides in the 5′ and 3′ splice sites most frequently yield human diseases. These dinucleotides are fundamental for exon definition and appropriate splicing. However, mutations occurring at positions distal to the 5′ and 3′ splice sites can also lead to aberrant splicing, and typically lead to exon skipping. In this study, we found that a single base substitution between 5′ and 3′ splice site boundaries (c.2137-18G>A) led to exon skipping [20] [21] [22] . By in silico analysis, the intronic variant did not affect the splicing consensus site, branch site, or polypyrimidine tract; however, it disrupted the SF2/ASF binding site, in which the ISE protein works. This may be the cause of exon skipping by the intronic variant, c.2137-18G>A (Supplementary Figs. 7 and 9 ). When we evaluated the pathogenicity of the two variants in accordance with the American College of Medical Genetics and Genomics guideline, both variants demonstrated very strong evidence of pathogenicity (intron 19 variant: PSV1+PS3, PS4+PM2; exon 8 variant: PSV1+PS3), justifying classification as pathogenic variants [23] .
One study reported six individuals with NUP93 mutations who developed SRNS at onset ages between 1 and 6 years old, and who progressed to ESRD between the ages of 1 and 11 years old with FSGS as the primary histological finding [14] . Compared with our patient, the phenotypes are almost identical. To confirm the pathogenicity of the intronic variant in the relevant cell type (i.e., kidney cells), we repeatedly attempted to transfect hybrid minigene constructs into podocytes. However, we were unsuccessful because of the low transfection efficacy of podocytes [24] ; this was another important limitation of our study.
In conclusion, by the use of some simple molecular techniques, we defined the pathogenicity of a very rare intronic variant in NUP93. In both clinical and laboratory settings, this assay can be used to clarify the pathogenicity and disruption of complex splicing mechanisms, as well as to yield clues regarding the underlying causes of rare diseases.
